Which trends dominated hospital M&A activity last year?

The latest stories trending on MedCity News.

Editor's Pick

Top Story Which Trends Dominated Hospital M&A Activity Last Year? M&A activity among health systems picked up last year — key trends included cross-market mega-mergers and academic medical centers expanding their community hospital networks. Despite tough economic conditions, Kaufman Hall experts expect this activity to continue growing in 2023. Sponsored How L&D in Regulated Industries Can Move Beyond Just Compliance to Impact Presented by Emergn and MedCity News The Covid-19 pandemic has forced life sciences companies to take a fresh look at how they do business. But as they reinvent their operations, companies often overlook a critical function: their learning and development (L&D) programs. Learn More

Featured News

Claiming Insulin Price Conspiracy, CA Sues Lilly, Novo Nordisk, Sanofi & PBMs California's Office of the Attorney General contends that drugmakers and pharmacy benefit managers work together to "aggressively raise the list price of insulin in lockstep with each other to artificial levels." Insulin manufacturers deny the allegations, pointing to availability of lower-cost versions of their products. Microsoft Strikes Partnership with Paige To Advance Cancer Diagnostics and Treatment Microsoft is making a strategic investment in Paige, which is leveraging AI for cancer diagnostics and treatment. Paige will also use Microsoft Azure as its cloud provider for the Paige Platform. Meet the First Startup to Come Out of UC Davis Health's Innovation Incubator UC Davis Health announced the first startup to come out of its health tech innovation incubator. The company, named WellCent, is a platform that allows patients and caregivers to onboard medical devices into their home and access digital health resources. Dr. B Adds New Treatments to Platform, Expands Beyond Covid-19 Dr. B began as a virtual service providing access to Covid-19 vaccines and later Covid-19 treatments. It has now expanded to treatments for dermatology, sexual health, reproductive health and primary care. Roche Influenza Antiviral Gets European Commission Approval for Young Kids Xofluza, a flu antiviral drug developed by Roche and Shionogi, is now approved in Europe for children age 1 and older. The European Commission decision expands the patient population for the drug, which was previously approved for treating adolescents and adults.

Resources

Free eBook: "Startup 101: Providing Best Practices for Healthcare Entrepreneurs" Get the tools necessary to make the right decisions, know what strategies to avoid, and learn how to approach potential healthcare customers. Download Now

MedCity News • 611 Broadway • New York, NY unsubscribe